Climb Bio Reports Q3 Non-GAAP EPS of -$0.18, Exceeding Estimates
Climb Bio (CLYM) reported third-quarter non-GAAP earnings per share of -$0.18, slightly surpassing market expectations by $0.02. The results reflect the company's ongoing financial performance as it manages its current operating plan. As of September 30, 2026, the company maintained a strong liquidity position with $227.6 million in cash, cash equivalents, and marketable securities. Management stated that these funds are expected to support operations through at least the second half of the upcoming period.
Tickers: $CLYM